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ABSTRACT: Misfolding of mutant enzymes may play an
important role in the pathogenesis of cystathionine
b-synthase (CBS) deficiency. We examined properties
of a series of 27 mutant variants, which together
represent 70% of known alleles observed in patients
with homocystinuria due to CBS deficiency. The median
amount of SDS-soluble mutant CBS polypeptides in the
pellet after centrifugation of bacterial extracts was
increased by 50% compared to the wild type. Moreover,
mutants formed on average only 12% of tetramers and
their median activity reached only 3% of the wild-type
enzyme. In contrast to the wild-type CBS about half of
mutants were not activated by S-adenosylmethionine.
Expression at 181C substantially increased the activity of
five mutants in parallel with increasing the amounts of
tetramers. We further analyzed the role of solvent
accessibility of mutants as a determinant of their folding
and activity. Buried mutations formed on average less
tetramers and exhibited 23 times lower activity than the
solvent exposed mutations. In summary, our results show
that topology of mutations predicts in part the behavior
of mutant CBS, and that misfolding may be an important
and frequent pathogenic mechanism in CBS deficiency.
Hum Mutat 31:809–819, 2010. & 2010 Wiley-Liss, Inc.
KEY WORDS: homocysteine; cystathionine b-synthase
deficiency; CBS; homocystinuria; folding; misfolding;
topology; E. coli
Introduction
Cystathionine b-synthase (CBS) deficiency (MIM] 236200, also
known as homocystinuria due to CBS deficiency) is a well-known
multisystemic inborn error of metabolism with widely varying
estimates of frequency. Although the number of patients with
clinically ascertained CBS deficiency is rather low and the
prevalence is only 1:330,000 worldwide [Mudd et al., 2001], the
molecular epidemiological studies suggest an incidence of around
1:10,000 in several European populations [Gaustadnes et al., 1999;
Janosik et al., 2009; Refsum et al., 2004]. Classical form of this
disease manifests by combination of neurological, connective
tissue, and vascular involvement in childhood, whereas milder
form of the disease may be diagnosed later in adulthood with only
vascular manifestation. Severity of the untreated disease is
determined mostly by the underlying genetic defect, and patients
with milder forms of CBS deficiency usually respond to
pharmacological doses of pyridoxine by a marked decrease of
their total homocysteine plasma levels.
More than 150 mutant alleles have been described in patients
with CBS deficiency with a representation of all types of genetic
variants (http://www.uchsc.edu/cbs/cbsdata/cbsmain.htm). Mis-
sense mutations are the most common variants described
in the CBS gene, representing 87% of the 753 analyzed patient-
derived CBS alleles as of April 2010. In a previous study we
have proposed that missense CBS mutant enzymes may
misfold, and that this behavior may be responsible for their
pathogenicity [Janosik et al., 2001b]. This observation was later
confirmed by other groups and also by expressing mutants in
systems other than Escherichia coli (for references, see Table 1).
The finding that misfolding and decreased activities of some
mutant proteins may be corrected with the help of chemical
chaperones further supports the role of misfolding in the
pathogenesis of CBS deficiency [Singh et al., 2007]. Despite many
years of research novel data on structural and biochemical
properties of CBS mutant proteins are scattered in the literature,
and a comprehensive analysis of the folding-related findings is
missing.
In this study, we examined systematically catalytic and
folding-related structural properties of a panel of 27 mutants
located in different functional domains of the CBS molecule.
The panel of mutations contained, among others, the most
prevalent mutant CBS alleles to well represent the molecular
mechanisms relevant for the majority of patients suffering from
CBS deficiency. Because purification of CBS mutant proteins for
further studies is not universally achievable, we decided to study
properties of mutant proteins in crude E. coli extracts, thus
obviating any possible loss of mutants during the purification
procedure. We studied the solubility of the mutant proteins in
sodium dodecyl sulfate (SDS), their oligomeric structure, activity,
response to S-adenosylmethionine (AdoMet) and S-adenosylho-
mocysteine (AdoHcy), and changes of these parameters after
expression at a decreased temperature. We subsequently examined
whether the location of mutant residues in the three-dimensional
CBS structure in respect to solvent accessibility is a determinant of
their properties. We show that mutations of residues buried in
protein globule appear to have more severe effect on folding than
those exposed to the solvent.
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Nucleotide and Codon Numbering
Nucleotide numbering reflects the cDNA numbering with 11
corresponding to the A of the ATG translation initiation codon in
the reference GenBank sequence NM_000071.2, according to the
Journal guidelines (www.hgvs.org/mutnomen). The initiation
codon is codon number 1.
Molecular Dynamics Simulation
In silico analyses presented in this article can be divided in two
parts. The first part presents an analysis of mutant structures of
catalytic domain of CBS, and the second part presents analysis of
CBS regulatory domain. X-ray structure of the active core of the
CBS protein (PDB code 1JBQ) [Meier et al., 2001] was utilized as
the starting model for the catalytic domain. 1JBQ X-ray structure
contains the first 413 residues of the protein and covers the whole
catalytic domain. First, we optimized the native structure in
program Modeller (http://salilab.org/modeller) [Sali and Blundell,
1993], which combines empirical spatial restraints and a
CHARMM force field into an objective function and employs
conjugate gradients and molecular dynamics with simulated
annealing methods for energy optimization. Model refinement
level property of the Modeller procedure was set to very low. In
the next step the optimized native structure was mutated in silico,
and mutant structures were optimized in the same way.
Although a model of the regulatory domain of human CBS
(residues 415–543) has been published a few years ago [Sen et al.,
2005] the X-ray structure of this part of the CBS molecule is as yet
unknown. We generated our own model of this portion of the
wild-type CBS using the comparative structure modeling. As the
initial model we used X-ray structure of the conserved CBS
domain of the protein TA0289 from Thermoplasma acidophilum
(PDB code 1PVM) [Proudfoot et al., 2008]. Sequence of the CBS
regulatory domain was aligned with the TA0289 sequence and
coordinates of its native structure were derived from the 1PVM
coordinates (data not shown). The native structure was then
optimized and mutant structures were computed as in case of the
active core. For the native as well as all computed mutated
structures of both domains, the surface accessible area of amino
acid residues was calculated and normalized by maximum
accessible surface area for the corresponding residue type by the
program Modeller [Sali and Overington, 1994]. A residue was
considered exposed if its accessible surface area was larger than 40
A
2 and/or if its relative accessible surface was larger than 9%, while
considered buried otherwise [Mirkovic et al., 2004].
Expression in E. coli
The wild-type CBS and mutant constructs were derived from
the pHCS3 expression plasmid [Kozich and Kraus, 1992]. Seven
mutant plasmids, namely, the c.341C4T (p.A114V), c.442G4A
(p.G148R), c.526G4A (p.E176K), r.1224_1358del; p.W409_G453del,
c.1265C4T (p. P422L), c.1304T4C (p.I435T), and c.1397C4T
(p.S466L) were prepared using the previously described procedure
of replacing a fragment of wild-type CBS expression plasmid with
the equivalent restriction fragment derived from the mutant
patient-derived cDNA [Kozich and Kraus, 1992]. The remaining
mutations were introduced into the wild-type expression plasmid
by help of the GeneTailor site-directed mutagenesis kit (Invitrogen,
Carlsbad, CA) according to the manufacturer’s procedure. The
sequences of mutagenic primers are given in Supp. Table S1.
The authenticity of all constructs was verified by dideoxy
sequencing using ALF sequencer (Amersham Pharmacia Biotech,
Piscataway, NJ).
The expression plasmids were used to transform E. coli DH5a
cells (Gibco BRL, Carlsbad, CA). The cells were grown at 37 or
181C in SOB (Super Optimal Broth) media with 100mg/ml
ampicilin to OD600 of  0.5, expression of CBS was carried out in
the presence of isopropyl b-D-1-thiogalactopyranoside (final
concentration 0.33mmol/l) at 37 or 181C for 3hr or overnight,
respectively. Each mutant protein was expressed in at least five
independent experiments on separate days (i.e., three and two
expression at 37 and 181C, respectively). Each series of mutant
proteins contained also bacteria transformed with the pKK388.1
vector lacking the CBS insert as a negative control, and the wild-
type CBS that was used to normalize data.
Lysates from E. coli cell pellets were prepared by sonication in
lysis buffer (50mmol/l Tris-Cl pH 8, 10mmol/l EDTA, 1mmol/l
DTT, 0.1% lysozyme) with the addition of commercial Protease
Inhibitor Cocktail (Sigma Aldrich, St. Louis, MO) according to
manufacturer‘s protocol. A 50-ml aliquot of each sonicate was
saved for the analysis of CBS in the particulate and nonparticulate
fraction, the remaining sonicate was centrifuged at 15,000   g for
30min at 41C, and the supernatant was aliquoted and stored for
subsequent analyses at  851C. Protein concentration in the
supernatant was determined by the method of Lowry with bovine
serum albumin as a standard [Lowry et al., 1951].
Optimizing Extraction of Aggregated CBS
We tested several methods that have been previously used by
other authors to extract aggregated proteins, such as amyloid,
from bacterial lysates [Carra et al., 2005]. Optimization was
carried out with the wild-type CBS and four mutant enzymes
(p.A114V, p.V180A, p.K102N, and p.I278T). We have compared
the effects of the following denaturing reagents: (1) 1.5% SDS in
the presence of 0.1 M b-mercaptoethanol (without preincuba-
tion), (2) 3% SDS in the presence of 0.1 M b-mercaptoethanol
(without preincubation), (3) 6 M urea, 1.5% SDS, and 0.1M
b-mercaptoethanol (1hr incubation at room temperature), (4) 6
M urea/thiourea (v/v 2:1) containing 1.5% SDS and 0.1M
b-mercaptoethanol (1hr incubation at room temperature), and
(5) 100% formic acid (30 min incubation at 371C) followed by a
lyophilization and dissolution in denaturating solution containing
1.5% SDS and 0.1M b-mercaptoethanol. After incubation of
uncentrifuged sonicates with different denaturing reagents for the
indicated time the samples were boiled for 10min at 1001C and
analyzed by SDS-PAGE and Western blotting as described below.
These experiments revealed, that methods (2) and (5) provided a
higher yield of immunoreactive CBS signal compared to the other
methods. Owing to a simplicity and a sufficient efficacy of method
(2), we subsequently used the extraction of insoluble CBS from
pelets and supernatants by 3% SDS.
Analysis of Particulate and Nonparticulate Fraction
Fifty microliters of sonicated cell extracts were centrifuged at
41C at 15,000 g for 30min, the supernatants were saved and the
pellets were resuspended in 50mL of denaturation buffer
(50mmmol/l Tris-Cl pH8, 0.1mol/l b-mercaptoethanol, 3%
SDS). To solubilize the CBS present in the samples 5mL of either
the resuspended particulate fraction or of the supernatant were
mixed with 15mL of the denaturation buffer and boiled at 1001C
for 10min; subsequently, 4mL of electrophoresis loading buffer
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solution was heated for 10min at 1001 prior to loading on the
SDS-PAGE gel. Samples of the supernatant and particulate fraction
of each mutant protein were loaded next to each other on the gel
and subjected to electrophoresis and Western blot analysis (see
below the section Electrophoresis and Western Blot Analysis); each
gel also contained the supernatant and particulate fraction of a
negative control and of bacteria expressing wild-type CBS. The
sharply demarcated signal of CBS in each fraction was quantified
by chemiluminescence after subtracting the background of the
negative control. For each mutant the signal in the supernatant and
the particulate fractions were added, thus yielding the total CBS
antigen of the respective mutant. This total signal was subsequently
normalized to the total signal of wild-type CBS enzyme after
correction for the protein concentration.
Electrophoresis and Western Blot Analysis
Separation of CBS under denaturing conditions was carried out in
4–15% gradient native polyacrylamide gels (Criterion Precast Gel,
BioRad, Hercules, CA) with standard Laemmli SDS-containing
buffer system [Laemmli, 1970]. For the analysis of CBS under native
conditions cell lysates containing 10mg of total protein were
separated using the same precast polyacrylamide gels with standard
Laemmli buffer system without SDS [Laemmli, 1970].
Proteins separated by either SDS-PAGE or native PAGE were
transferred onto polyvinylidene difluoride membrane (Immobilon-P,
Millipore, Billerica, MA) using semidry blotting transfer technique.
After transfer nonspecific binding sites were blocked by overnight
incubation with 5% nonfat dry milk in 1  phosphate-buffered
saline solution (PBS), pH 7.0, and 0.2% Tween 20. The membrane
was subsequently incubated with immunopurified anti-CBS
antibody diluted 1:5,000 in 1 PBS containing 3% bovine serum
albumin for 1hr and after a series of washes with secondary
antirabbit IgG antibody conjugates with HRP (Pierce, Rockford,
Il) for 30min. The secondary antibody was diluted 1:30,000
in 1 PBS/0.2% Tween 20 containing 5% nonfat dry milk. After
a second series of washes the signal was visualized using the
West Pico Super Signal system (Pierce Biotechnology), followed
by bioimaging system ChemiGenius-Q (Syngene Inc., Federick,
MD) with a cooled CCD camera. The amount of sharply
demarcated fractions of tetramers and oligomers and of fuzzy
high-molecular weight aggregates were quantified with Gene
Tools software (Syngene Inc.) after the subtraction of back-
ground on an E. coli extract lacking CBS that was analyzed in each
series.
Estimation of Molecular Weight by Ferguson Plot
Molecular weight of CBS fractions with varying mobility was
estimated using a modification of the method published by
Ferguson [Ferguson, 1964; Hedrick and Smith, 1968]. The original
method is based on electrophoresing the analysed protein together
with markers in a series of polyacrylamide gels with increasing
concentration of acrylamide. We have determined the relative
mobilities normalised to the dye front (Rf) of commercial
molecular mass markers (Blue Range, Pierce) ferritin (440kDa),
catalase (232kDa), urease (272 and 545kDa), bovine serum
albumin (BSA) (66 and 132kDa), and egg albumin (45kDa) using
10-cm long 5, 6, 7, 8, 9, and 10% native polyacrylamide gels and
Laemmli electophoresis buffers without SDS [Laemmli, 1970]
after staining of the gels by Coomassie blue R The E. coli extracts
containing mutant and wild-type CBS were separated by the same
series of polyacrylamide gels, the CBS fractions were visualized by
Western blotting and immunodetection as described above, and
the relative mobilities normalizes to the dye front have been
determined.
The logarithms Rf of each band of the standard proteins were
plotted against the acrylamide gel concentrations, and the slope of
regression line of each standard protein was calculated. The
calibration line was derived as a function of the logarithms of
negative slopes and the molecular weights of the standard. The
negative slopes of all oligomeric forms of wild-type CBS and of
selected mutant proteins were determined by the same method,
and these values were used for calculation of molecular weight of
the different CBS fractions. The bacterial extracts used for this
analysis contained the wild-type CBS, the p.K102N, p.S466L,
p.E302K, p.G305R, p.G307S, and p.R125Q variant proteins
expressed at 181C.
CBS Enzymatic Assay
The CBS activity in E. coli lysates was assayed by modification
of the previously published procedure [Kozich and Kraus, 1992].
The assay mixture contained 100mM Tris-HCl (pH 8.6), 0.5mg/ml
BSA, 0.5mM pyridoxal 50-phosphate, 1mM dithiothreitol, 10mM
homocysteine, 10mM 2,3,3-
2H-labeled serine (Cambridge Isotope
Laboratories) and 27.5mlo fE. coli extract in lysis buffer
containing 75mg of bacterial protein. The assay mixture was
incubated at 371C for 1hr in a total volume of 50ml. For
measurement of responsivity to adenosyl compounds the assay
mixture contained either 0.5mM AdoMet or AdoHcy. The activity
was determined by the LC-MS/MS measurement of the product of
enzyme reaction, 3,3-
2H-labeled cystathionine, using the com-
mercially available kit for amino acid analysis (EZ:faast,
Phenomenex, Torrance, CA) (Krijt et al., unpublished).
Statistical Analyses
Means, standard deviations, and medians were determined
using the spreadsheet Microsof Office Excel 2003 (Microsoft,
Czech Republic), linear regression analysis was carried out using
the same software.
Results
Selection of Mutations and In Silico Analysis
To gain clinically as well as mechanistically relevant insight into
the role of misfolding in CBS deficiency we first selected a series of
naturally occurring CBS mutations for further laboratory studies.
The set of nine most prevalent mutations having a frequency of at
least 10 alleles in the CBS Mutation Database was selected; these
included the p.A114V, p.R125Q, p.E144K, p.T191M, p.R266K,
p.I278T, p.G307S, p.W409_G453del, and p.D444N. This set was
expanded by additional 18 less frequent mutations known to be
localized in different domains of the CBS protein [Meier et al.,
2001, 2003]. For the list of mutations see Table 1; location of the
mutations in the CBS active core and in the modeled
carboxyterminal domain is shown in Figure 1. The final series
reflects the molecular pathology of CBS deficiency as these 27
mutations are present on about 70% of all pathogenic CBS alleles
known in humans to date.
Based on our previous work [Singh et al., 2007], we
hypothesized that CBS mutations of residues buried in protein
globule may have more severe effect on folding than those exposed
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silico analysis with calculation of the solvent-accessible surface
area. Based on previously published criteria we considered mutant
residues with relative and absolute solvent-accessible surface area
higher than 9% and/or 40 A
2, respectively, as being solvent
exposed while the rest of the mutations were considered being
buried in the globule [Mirkovic et al., 2004]. Table 1 shows the
predicted solvent accessibility and demonstrates that mutations
belonging to these two classes are represented almost equally in
the series of 27 variant proteins.
Total Amount of CBS Mutant Proteins Expressed in E. coli
and Their Solubility
It has been shown previously that some CBS mutant proteins
expressed in bacteria misassemble and aggregate [de Franchis
et al., 1999; Gaustadnes et al., 2002; Janosik et al., 2001b; Singh
et al., 2007; Yamanishi et al., 2006]. It is conceivable that
aggregated mutant CBS polypeptides will form inclusion bodies,
and that a substantial fraction of misfolded CBS proteins may thus
escape detection if the commonly used supernatant fraction of
bacterial extracts is utilized for Western blotting analysis.
To test this assumption we first optimized a method for
extracting water-soluble as well as aggregated and water-insoluble
CBS from bacteria expressing wild -ype and four mutant enzymes
(for details, see the Methods section). Boiling in 3% SDS was
subsequently used for the entire series of 27 mutant proteins to
determine the amount of CBS antigen in both the particulate (i.e.,
pellet after centrifugation) and nonparticulate (i.e., supernatant)
fractions of sonicated bacterial extracts. The sum of CBS signal in
both fractions is referred to as the total SDS-soluble CBS antigen.
Using the SDS extraction we observed that all 27 mutant proteins
were present in detectable amounts not only in the supernatants but
more importantly also in the particulate fractions of the bacterial
extracts. The presence of CBS antigen in both fractions is shown in
Figure 2; however, this publication gel does not allow inferring either
on relative proportions of the mutant proteins in the supernatant and
particulate fractions or on their relation to the wild-type enzyme (for
details, see the Methods section and legend to Fig. 2). The signal of
total SDS-soluble CBS antigen of the mutant proteins was generally
somehow decreased with a median of 66% of the wild-type CBS (see
Supp. Table S2; gels used for quantification are not shown), although
some variant proteins were present in increased quantities. These data
suggest that compared to the wild-type enzyme the majority of
mutant CBS proteins are less stable in E. coli;h o w e v e r ,w ec a n n o t
exclude that some of them are also less soluble in 3% SDS.
Proportion of the SDS-soluble CBS antigen, which is present in
the particulate fraction, indicates the propensity of the mutant
protein to form high molecular weight aggregates and inclusion
bodies. The particulate fraction of the wild-type CBS lysates
contained only 12% of antigen of the total SDS-soluble signal,
while more of the signal in the pellet was observed for the mutant
proteins (median value was 18% of the total SDS-soluble antigen,
with a range of 5 to 50%; see Supp. Table S2). These data lend
support to our hypothesis that the mutant proteins in this study
were in general more prone to formation of large molecular weight
aggregates and/or inclusion bodies. This part of our study further
indicates that the previously reported analyses of mutants CBS in
the supernatants of centrifuged bacterial extracts [Kozich et al.,
1993] may have underestimated the steady-state amounts of
mutant proteins present in bacteria, and that extraction by 3% SDS
is needed to recover the insoluble aggregated molecular species.
Impaired Quaternary Structure of Mutant Proteins as a
Measure of Their Misfolding
The published data strongly support the hypothesis that CBS
deficiency may be a conformational disease caused by misfolding
of mutant enzymes. Detailed studies of folding, however, require
protein purification, which would be especially difficult to
accomplish for the most severely affected CBS enzymes. Because
misfolded polypeptide chains cannot be correctly assembled and
tend to form aggregates, we examined the quaternary structure of
the mutant proteins in the nonparticulate fraction of crude
bacterial extracts as a surrogate marker of their folding status. To
assess the oligomeric structure of the mutant CBS enzymes we
used electrophoresis in gradient polyacrylamide gels under
nondenaturing conditions followed by Western blotting.
Visual inspection of blots showed variable amounts of fuzzy and
putatively misassembled CBS, and largely differing amounts of clearly
demarcated CBS tetramers or higher order oligomers as shown in
Figure 2. Subsequent quantitative analysis of the blots revealed that
88% of the total water-soluble antigen of the wild-type CBS is present
as tetramers/oligomers. In contrast, these correctly assembled fractions
were substantially decreased in our set of mutant proteins (median
tetrameric/oligomeric signal was only 31% of the total water-soluble
CBS antigen, range 1–92%; data are given in Supp. Table S2). Because
the CBS antigen in the nonparticulate fraction of mutant proteins was
also decreased to a median 60% compared to the wild-type, the
Figure 1. Location of studied mutations in three-dimensional CBS structure. A: Mutations located at the surface of the active core are shown
in magenta, pyridoxal 50-phosphate (PLP) is shown in yellow. B: Mutations buried within the active core are indicated in green, heme and PLP
molecules are shown in red and yellow, respectively. C: Mutations located at the surface of the carboxyterminal regulatory CBS domain are
shown in red.
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severely reduced (median 12% of tetramers compared to the wild-
type CBS). There was no clear correlation between the location of
mutant proteins in different domains and their misfolding with the
exception of mutant proteins in the carboxyterminal domain that
were mostly assembled correctly. In summary, the above analyses
demonstrated that a substantial proportion of CBS mutant proteins
formed severely reduced amounts of correctly assembled tetramers;
these findings add further support to the notion that misfolding is an
important pathogenic mechanism in CBS deficiency.
Different Mobility of CBS Mutant Proteins in Native
Westerns
The above-mentioned Western blot analysis revealed slight but
consistent differences in migration distance of the putative
tetramers/oligomers of many mutant proteins in comparison to
the wild-type CBS tetramer (see Fig. 2). These mobility alterations
may have resulted from charge differences, conformational
changes of tetramers, or even different number of subunits in
the differently migrating fractions. To explore the latter hypothesis
we used the Ferguson plot to determine the molecular weight of
four fractions seen for wild-type enzyme, and the molecular
weight of fast migrating (K102N, S466L), slow migrating (E302K,
G305R, and G307S) and fast/slow migrating (R125Q) mutant
proteins. For results see Supp. Figure S1.
The apparent molecular weights of sharply demarcated and
thus presumably correctly assembled oligomer fractions seen for
the wild-type enzyme were 177, 398, 512, and 724kDa.
Considering the limitations of the technique employing crude
extracts with subsequent Western blotting and keeping in mind
that CBS is known to form tetramers, the results suggest that in
Figure 2. Amounts of mutant CBS antigen in fractions of bacterial extracts. A: Mutant proteins expressed at 371C; B: Results of expression of
mutant proteins at 181C. Top part of panels. The amount of SDS-soluble CBS antigen in particulate (Pel, pellet) and nonparticulate (Sup,
supernatant) fractions of bacterial extracts obtained by centrifugation was determined by SDS-PAGE and Western blotting as described in the
Methods section. The blots in this figure are only shown to demonstrate the presence of CBS antigen in both fractions and do not reliably reflect
the proportion between the fractions; the particulate fractions and the supernatant fractions were loaded on separate gels, whereas in the
experimental blots used for quantification these two fractions of each mutant were loaded next to each other on the same gel (data not shown).
Only a single representative sample from two to three independent expression experiments has been loaded for this publication gel. Bottom part
of panels. The quaternary structure of CBS mutants was assessed in the water-soluble nonparticulate fraction of bacterial extracts by
electrophoresis under native conditions followed by Western blotting; sharply demarcated fractions are tetramers and higher oligomers. Only a
single representative sample from two to three independent expression experiments has been loaded for this publication gel. Solvent exposed
mutations, mutations with accessible surface area larger than 40 A
2 and/or with relative accessible surface larger than 9% (with the exception
of mutations p.C165Y, p.P422L, and p.S466L that belong to buried mutations) buried mutations, remaining mutations from the panel are grouped
here (with the exception of mutation p.H65R that belong to solvent exposed mutations). WT, bacterial extracts containing wild-type CBS; pKK
388.1, extracts of bacteria transformed with the empty pKK 388.1 plasmid lacking any CBS.
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predominantly in the form of tetramers, and in small amounts
also as octamers, dodecamers, and hexadecamers. Two fractions of
the R125Q mutant protein were predicted to be composed of
tetramers and octamers, respectively. There was only a small
difference in slopes, and thus in estimated molecular weights of
the remaining fast (162 and 166kDa) and slow (199–213kDa)
migrating mutant proteins as demonstrated in Supp. Figure S1.
Consequently, the estimated number of CBS subunits ranged
between 2.7 and 3.5 per fraction, which is congruent with
tetrameric composition of these fractions. In summary, the results
of Ferguson plot do not support a hypothesis that different
mobility of mutant proteins compared to wild-type CBS is caused
by changes in the number of enzyme subunits. Thus, the observed
varying mobility of CBS mutant proteins results most likely from
subtle changes in the shape and/or charge of the assembled
tetramers.
Catalytic Activity of Mutant Proteins
To enable measurements of low residual activities of mutant
proteins we first developed a sensitive method for the analysis of
the CBS reaction product—cystathionine. The radioactive sub-
strate used in previous studies,
14C-labeled serine, was replaced by
2,3,3-
2H-labeled serine, and the amount of 3,3-
2H-labeled
cystathionine produced was determined using LC-MS/MS (Krijt
et al., unpublished). Using this technique, we were able to measure
reproducibly activities as low as 0.3nmol cystathionine/hr/mg of
protein, which represents about 0.2% of the average wild-type
CBS activity in E. coli extracts.
Using the sensitive new assay we observed an extreme variation of
activities ranging from 0 to 245% of the wild-type enzyme with a
median activity of 3% of the wild-type CBS (for details, see Table 2).
Only three mutant proteins—p.G305R, p.T262R, and p.N228K—
did not exhibit any measurable residual activity above 0.3nmol/mg/
hr, whereas the remaining 24 mutant proteins had above-threshold
activity in at least two of the three independent expression
experiments. The activities determined in the present study are for
the majority of mutant proteins congruent with the previously
published values listed in Table 1. In contrast to effects on folding
location of the mutant residues appears to play a more important
role in affecting their catalytic activity of variant proteins. There
was a tendency for mutations located in the active site, heme
binding pocket, and elsewhere in the active core to exhibit rather
low activities while mutations inside or on the surface of the first
CBS domain and at the dimer–dimer interface were in many cases
as active as the wild-type enzyme (for details, see Table 2). These
data suggest that mutations in different domains of the enzyme
may have substantially variable impact on its catalytic activity, and
that they may not affect folding and activity simultaneously.
Effect of AdoMet and AdoHcy on the Catalytic Activity
of Mutant Proteins
To get an insight into the possible pathophysiological and
therapeutic implications of AdoHcy and AdoMet in CBS
deficiency we studied the effect of these two compounds on the
activity of mutant proteins in nonparticulate fractions of bacterial
extracts. Blood concentration of AdoHcy is increased in patients
with CBS deficiency [Orendac et al., 2004] due to its reverse
synthesis from homocysteine and adenosine with the help of
AdoHcy hydrolase, an enzyme that can be in vitro blocked with
different inhibitors. AdoMet is an allosteric activator of CBS that
can possibly stimulate the residual activity of mutant proteins and
that can be administered as a drug in the form of tosylate.
Activity of the wild-type CBS enzyme increased 3.9  and
1.3  in the presence of 0.5mM AdoMet and 0.5mM AdoHcy,
respectively (see Table 2). Because activation of CBS by AdoHcy
has not yet been reported, we explored whether it could not have
been caused by contamination of this compound by AdoMet.
However, LC-MS/MS analysis showed that the AdoHcy standard
contained less than 1% of AdoMet, indicating that the 1.3 
increase in wild-type CBS activity in crude bacterial extracts can
be attributed to AdoHcy itself.
We classified without formal statistical testing the response of
mutant proteins to AdoMet and AdoHcy in this simple screening
system as follows: clear activation similar to the wild-type enzyme,
clear inhibition, or absence of expected activation. About one-half
of the mutant enzymes in the panel exhibited an unusual response
to either one of the adenosyl compounds: the p.E176K was
inhibited by AdoMet, the p.E302K was inhibited by AdoHcy, and
the p.H65R, p.T191M and p.C165Y appeared to be inhibited by
both adenosyl compounds. In addition, mutations p.E302K,
p.W409_G453del, p.I435T, p.L539S, p.E144K, p.G148R, p.G307S,
p.I278T, and p.S466L were not activated by AdoMet to an extent
that was usually observed for the wild type CBS (see Table 2).
These data show that responses of about half of mutant proteins
to AdoMet and AdoHcy may differ substantially from those of the
wild-type CBS. The relevance of these findings for regulation of
the activity of mutant proteins and possibly for treatment of CBS
deficiency is further explored in the Discussion section.
Effect of Low Temperature on Properties of Mutant
Proteins
Low temperature during expression has been shown to enhance
folding of various mutant proteins that are prone to misfolding.
To examine whether any of the CBS mutations under study may
be rescued by more folding-permissive conditions we expressed all
27 mutant proteins at 181C. Compared to expression at 371C the
lower temperature has not dramatically changed the total amount
of SDS-soluble mutant CBS enzymes and only slightly decreased
the proportion of signal in the particulate fraction (median of
18% at 371C vs. 15% of total signal at 181C; see Supp. Tables S2
and S3). However, the median amount of correctly folded
oligomers in the water-soluble nonparticulate fraction detected
on native-PAGE increased about two times from 31% of total
signal at 371Ct o6 8 %o ft o t a ls i g n a la t1 8 1C (Supp. Table S2 and S3).
Several mutant proteins responded to low expression temperature
with a dramatic (i.e., more than approximately threefold) increase
of the proportion of tetramers compared to the proportion of
tetramers/oligomers of the wild-type CBS, namely, the p.R266K,
p.R369C, p.R125Q, p.P78R, p.V180A, and p.I435T. However,
this folding promoting effect of low temperature was not universal
and some mutant proteins produced conversely less tetramer. All
these observations indicate that for some mutant proteins more
folding-permissive conditions facilitate the attainment of correct
tertiary structure, which subsequently increases the assembly of
tetramers.
In addition, the low expression temperature increased the
median catalytic activity of mutant proteins from 3% of wild type
at 371C to a median of 13% of wild type at 181C (see Table 2). The
mutant proteins p.R266K, p.R125Q, p.R369C, p.V180A, and
p.P78R exhibited more than approximately twofold increase in
activity relative to the wild type, which correlated well with the
increased amount of tetramer. These five mutant proteins may be
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816 HUMAN MUTATION, Vol. 31, No. 7, 809–819, 2010considered true folding mutants as their residual activity directly
correlates with the amount of tetramer. In summary, the lower
expression temperature substantially increased activity of five
mutant proteins, further supporting the hypothesis that deficient
CBS activity may be in some instances caused by misfolding that
may be alleviated by folding permissive conditions.
Solvent Exposure of Mutant Residues as a Determinant
of Folding and Activity
We hypothesized that topology of mutations in respect to
solvent exposure/buriedness may have an impact on folding and
assembly of mutant CBS molecules. Therefore, we compared in
the next step the typical properties of CBS enzymes carrying
buried versus solvent-accessible mutations by comparing median
values in Table 2 and in Supp. Table S2 and S3. We have observed
similar stability of these two classes of mutant proteins in E. coli as
evidenced by identical amounts of total SDS-soluble antigen.
However, the propensity of buried mutations to correctly fold and
assemble is impaired, as clearly demonstrated by the lower
proportion of tetrameric/oligomeric fractions in the total CBS
antigen in native gels with a median of only 14% of total antigen
for buried mutations versus 36% for the solvent accessible ones.
More importantly, the buried mutations are about 23 times less
active with median activity of only 0.4% of the wild-type CBS
versus 9.4% of the wild-type enzyme for solvent-exposed
mutations. In addition, the buried mutations are not activated
by AdoMet (the median activation of buried mutations of 1.0 
contrasts with the 2.5  activation of solvent exposed mutation)
and seem to be inhibited by AdoHcy (median activation of buried
mutations is 0.8 , while it is 1.3  for solvent-exposed
mutations). These differences between buried and solvent-exposed
mutations appear to be further augmented by the expression at
181C. In summary, these comparisons strongly suggest that buried
mutations may lead to much severe impairment of CBS structure
and function than the solvent-exposed ones.
Expression of several mutant proteins at 181C resulted in an
increase in their catalytic activity as well as in the amount of
tetramers/oligomers; we therefore proposed that these variant
proteins may be considered true folding mutations. To evaluate
this phenomenon in a more systematic way we have plotted the
normalized activity of mutant proteins against the normalized
amount of tetramers/oligomers using the combined data from five
independent expression experiments. Supp. Figure S2 demon-
strates that among the solvent-exposed mutations there are indeed
examples of such increase of activities mirroring the increased
amounts of tetramers (e.g., p.A114V, p.H65R, p.K102N, p.P78R,
p.R125Q, and p.V180A). However, changes in amounts of
tetramers of buried mutations were not usually accompanied by
corresponding differences in activities. That led us to speculate
that the solvent exposure of mutations may be indeed an
important determinant of their propensity to misfold and to lose
the catalytic activity. We have next performed a regression analysis
in which we combined data for all buried and all solvent-exposed
mutant proteins, respectively. This analysis has demonstrated that
the activity of solvent-exposed mutations correlates quite strongly
with the amount of oligomers (r
250.53; see Fig. 3B), and suggests
that for this type of mutations enhanced folding achieved by, for
example, low temperature or chaperones may result in increased
residual activity. In contrast, the mutations buried in the enzyme
globule did not exhibit such properties, as there was only a weak
correlation between the activity and the amount of oligomers
(r
25.11; see Fig. 3A). The above-described regression analysis
suggests that solvent-exposed CBS mutations may be more likely
to respond to interventions aimed at correcting their misfolding.
Discussion
This article focused on testing in a systematic way the
hypothesis that misfolding plays an important role in CBS
deficiency. To examine the hypothesis we selected a representative
set of mutants located in different functional domains of the CBS
molecule. Several lines of evidence suggest that misfolding is an
important pathogenic mechanism in CBS deficiency: (1) the
amount of SDS-soluble mutant CBS polypeptides in a particulate
fraction was increased by 50% compared to the wild type, possibly
due to inclusion body formation; (2) the net yield of mutant
tetramers/oligomers in the nonparticulate water-soluble fractions
Figure 3. Solvent exposure and misassembly of mutants. (A) buried mutations; (B) solvent exposed mutations. Data on normalized activities
and tetramer amounts shown in Supp. Figure S2 are here combined separately for all solvent exposed and all buried mutations; J and
n indicate data for expression at 37 and 181C, respectively. Linear regression analysis shows much stronger correlation between activity and
the amount of tetramers for solvent exposed mutations than for the buried ones.
HUMAN MUTATION, Vol. 31, No. 7, 809–819, 2010 817was severely reduced to only 12% of the wild-type enzyme; and
(3) more folding permissive conditions (i.e., expression at 181C)
led to a doubling of tetramer amounts and partial restoration of
activity. The mutant proteins studied in our article represent
about 70% of known patient derived CBS alleles, and 18 of these
27 mutations clearly result into moderate to severe misfolding of
the CBS enzyme (i.e., formation of less than 25% of tetramer of
the wild type). This is an important finding that is relevant to 362
of 753 mutant alleles deposited in the CBS Mutation Database as
of April 2010; in other words, about one-half of all known
chromosomes affected by pathogenic mutations code for mutant
polypeptides that misfold and misassemble. Taken together, all
these data suggest that abnormal folding is an important and
common molecular mechanism in CBS deficiency.
An important finding of our study is the more important role
of solvent accessibility of mutations rather than their location in
enzyme domains in predicting properties of mutant enzymes. In
general, buried mutations exhibited much more profound
detrimental effect on enzyme folding and activity compared to
the solvent-accessible mutations. Appearance of sufficient
amounts of tetramers in native gels did not predict enzyme
activity for the buried mutants; however, increased tetramer
formation of surface mutants elicited by low expression
temperature led to an increase in residual activity. The plot of
activity versus amount of tetramer (see Fig. 3 and Supp. Fig. S2 )
shows a good correlation for solvent-exposed mutants, implying
that enzyme activity of these genetic variants is determined in part
by the amount of tetramers and in part by the precise location of
the mutant residue and the character of the change.
In this study we observed clearly abnormal response to AdoMet
and AdoHcy for about one-half of mutant proteins: (1) several
previously characterized mutants in the COOH-terminal regula-
tory region were hyperactive and were not further activated by
AdoMet [Dawson et al., 1997; Kluijtmans et al., 1996, 1999]; these
mutants were previously shown to have similar conformation to
that of the activated wild-type CBS with bound AdoMet; (2) in
contrast, another class of mutant proteins with low activity was
either not stimulated or was even inhibited by AdoMet; and (3)
several mutant proteins were inhibited by AdoHcy. It has been
shown previously that whole blood or plasma concentrations of
AdoHcy are grossly elevated and that the AdoMet levels are either
normal or increased in patients with CBS deficiency [Heil et al.,
2007; Orendac et al., 2003]. It is at present unknown whether the
disturbed AdoMet and AdoHcy metabolism in CBS deficiency may
modulate the residual activity of mutant enzymes and whether
these observations may have any therapeutic implications.
The major limitation of our work relates to the different
intracellular milieu of prokaryotic and eukaryotic cells, and
especially to the differences in folding machineries and in protein
surveillance/degradation systems. Therefore, the conclusions from
our study have to be taken with care and have to be validated by
analyses of mutant proteins that will be expressed in eukaryotic
cells or obtained from tissues of animal models of CBS deficiency.
Despite these limitations, utility of the simple bacterial expression
systems has been appreciated for their ability to demonstrate the
inherent predisposition of other mutant enzymes such as
phenylalanine hydroxylase towards aberrant folding and mis-
assembly [Waters, 2003].
The above-described observations may lead to the development
of new strategies for treating patients with CBS deficiency. The
most important implication is the potential of chaperones to
rescue to a varying extent the misfolding and decreased activity of
a substantial proportion of mutant proteins. We have shown
previously in a selected set of mutant proteins that chemical
chaperones may restore biological function of CBS mutants
[Singh et al., 2007]. In addition, we examined the effect of six
chemical chaperones or CBS ligands on a set of 27 mutant
proteins presented in this article, and we have observed an effect
of some of these compounds [Kopecka et al., in press]. However,
the practical utility of chemical chaperones for the treatment of
misfolding disorders is modest, and a more promising modality
would be the use of a specific pharmacological CBS chaperone
that awaits its discovery. The second group of treatment options
implied theoretically from our present study are the AdoHcy
hydrolase inhibitors that may decrease the concentrations of
AdoHcy and alleviate thus inhibitory effect of AdoHcy on some
mutant proteins, or the administration of AdoMet tosylate to
stimulate the residual activity of other mutant CBS enzymes.
AdoMet tosylate in doses of several hundreds of milligrams per
day has been used in treatment of liver disease, myopathies, and
depression without reports on adverse effects [Mato et al., 2001].
Whether or not chaperones and adenosyl compounds will be of
any use in patients with CBS deficiency and will impove quality of
their lives is presently unknown and needs to be explored in the
future.
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